EC Number | Activating Compound | Comment | Organism | Structure |
---|---|---|---|---|
3.4.22.26 | additional information | no activation with 0.005 mM cysteine and 4 mM KCN | Homo sapiens | |
3.4.22.26 | additional information | no activation with 0.005 mM cysteine and 4 mM KCN | Rattus norvegicus |
EC Number | General Stability | Organism |
---|---|---|
3.4.22.26 | Polyethylene glycol preparation yields stable enzyme | Homo sapiens |
3.4.22.26 | Polyethylene glycol preparation yields stable enzyme | Rattus norvegicus |
3.4.22.26 | Prefers lipid environment, phospholipids stabilize | Homo sapiens |
3.4.22.26 | Prefers lipid environment, phospholipids stabilize | Rattus norvegicus |
3.4.22.26 | Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum | Homo sapiens |
3.4.22.26 | Unstable hydrophobic enzyme which associates with other proteins or itself in tissue extracts and serum | Rattus norvegicus |
EC Number | Inhibitors | Comment | Organism | Structure |
---|---|---|---|---|
3.4.22.26 | alpha1-Aantichymotrypsin | weak | Homo sapiens | |
3.4.22.26 | alpha1-Aantichymotrypsin | weak | Rattus norvegicus | |
3.4.22.26 | alpha2-Macroglobulin | weak | Homo sapiens | |
3.4.22.26 | alpha2-Macroglobulin | weak | Rattus norvegicus | |
3.4.22.26 | antipain | enhanced in reduced environment | Homo sapiens | |
3.4.22.26 | antipain | enhanced in reduced environment | Rattus norvegicus | |
3.4.22.26 | diisopropylfluorophosphate | strong | Homo sapiens | |
3.4.22.26 | diisopropylfluorophosphate | strong | Rattus norvegicus | |
3.4.22.26 | HgCl2 | strong, less effective in reduced environment | Homo sapiens | |
3.4.22.26 | HgCl2 | strong, less effective in reduced environment | Rattus norvegicus | |
3.4.22.26 | iodoacetamide | strong, still enhanced in reduced environment | Homo sapiens | |
3.4.22.26 | iodoacetamide | strong, still enhanced in reduced environment | Rattus norvegicus | |
3.4.22.26 | leupeptin | enhanced in reduced environment | Homo sapiens | |
3.4.22.26 | leupeptin | enhanced in reduced environment | Rattus norvegicus | |
3.4.22.26 | additional information | cystatin, alpha1-antiprotease, antithrombin III | Homo sapiens | |
3.4.22.26 | additional information | cystatin, alpha1-antiprotease, antithrombin III | Rattus norvegicus | |
3.4.22.26 | Peptidyl chloromethanes | - |
Homo sapiens | |
3.4.22.26 | Peptidyl chloromethanes | - |
Rattus norvegicus | |
3.4.22.26 | Peptidyl diazomethanes | - |
Homo sapiens | |
3.4.22.26 | Peptidyl diazomethanes | - |
Rattus norvegicus | |
3.4.22.26 | Peptidyl dimethylsulfonium salts | - |
Homo sapiens | |
3.4.22.26 | Peptidyl dimethylsulfonium salts | - |
Rattus norvegicus | |
3.4.22.26 | phenylmethylsulfonyl fluoride | - |
Homo sapiens | |
3.4.22.26 | phenylmethylsulfonyl fluoride | - |
Rattus norvegicus | |
3.4.22.26 | trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane | enhanced in reduced environment | Homo sapiens | |
3.4.22.26 | trans-epoxysuccinyl-L-leucyl-amido(4-guanidino)butane | enhanced in reduced environment | Rattus norvegicus |
EC Number | Metals/Ions | Comment | Organism | Structure |
---|---|---|---|---|
3.4.22.26 | Ca2+ | requirement, 7 mM | Homo sapiens | |
3.4.22.26 | Ca2+ | requirement, 7 mM | Rattus norvegicus | |
3.4.22.26 | Mg2+ | 10 mM | Homo sapiens | |
3.4.22.26 | Mg2+ | 10 mM | Rattus norvegicus | |
3.4.22.26 | Mg2+ | requirement, can replace Ca2+ | Homo sapiens | |
3.4.22.26 | Mg2+ | requirement, can replace Ca2+ | Rattus norvegicus | |
3.4.22.26 | Mn2+ | requirement, can replace Ca2+ | Homo sapiens | |
3.4.22.26 | Mn2+ | requirement, can replace Ca2+ | Rattus norvegicus | |
3.4.22.26 | Mn2+ | but different binding site than Ca2+ (or Mg2+), 0.02 mM | Homo sapiens | |
3.4.22.26 | Mn2+ | but different binding site than Ca2+ (or Mg2+), 0.02 mM | Rattus norvegicus | |
3.4.22.26 | additional information | binding cancer procoagulant to a surface changes its divalent ion requirements | Homo sapiens | |
3.4.22.26 | additional information | binding cancer procoagulant to a surface changes its divalent ion requirements | Rattus norvegicus |
EC Number | Molecular Weight [Da] | Molecular Weight Maximum [Da] | Comment | Organism |
---|---|---|---|---|
3.4.22.26 | additional information | - |
- |
Rattus norvegicus |
3.4.22.26 | additional information | - |
amino acid composition of rabbit V2 and human amnion-chorion enzymes | Homo sapiens |
EC Number | Organism | UniProt | Comment | Textmining |
---|---|---|---|---|
3.4.22.26 | Homo sapiens | - |
- |
- |
3.4.22.26 | Rattus norvegicus | - |
- |
- |
EC Number | Oxidation Stability | Organism |
---|---|---|
3.4.22.26 | sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize | Homo sapiens |
3.4.22.26 | sensitive to oxidation of active site, 1 mM 2-mercaptoethanol and 5 mM KCN or 0.005 mM cysteine and 4 mM KCN stabilize | Rattus norvegicus |
EC Number | Posttranslational Modification | Comment | Organism |
---|---|---|---|
3.4.22.26 | no glycoprotein | no glycoprotein | Homo sapiens |
3.4.22.26 | no glycoprotein | no glycoprotein | Rattus norvegicus |
EC Number | Source Tissue | Comment | Organism | Textmining |
---|---|---|---|---|
3.4.22.26 | amelanotic melanoma cell | - |
Rattus norvegicus | - |
3.4.22.26 | carcinoma cell | - |
Rattus norvegicus | - |
3.4.22.26 | Lewis lung carcinoma cell | - |
Rattus norvegicus | - |
3.4.22.26 | additional information | unique in tumor | Homo sapiens | - |
3.4.22.26 | additional information | unique in tumor | Rattus norvegicus | - |
3.4.22.26 | additional information | unique in fetal tissues, not in normally differentiated tissues | Homo sapiens | - |
3.4.22.26 | additional information | unique in fetal tissues, not in normally differentiated tissues | Rattus norvegicus | - |
3.4.22.26 | placenta | amnion-chorion tissue | Homo sapiens | - |
3.4.22.26 | Walker carcinoma 256 cell | - |
Rattus norvegicus | - |
EC Number | Substrates | Comment Substrates | Organism | Products | Comment (Products) | Rev. | Reac. |
---|---|---|---|---|---|---|---|
3.4.22.26 | Factor X + H2O | primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19 | Homo sapiens | Factor Xa + ? | - |
? | |
3.4.22.26 | Factor X + H2O | primary cleavage site: Tyr21-Asp22, secondary sites: Asp14-Ser15 and Thr18-Glu19 | Rattus norvegicus | Factor Xa + ? | - |
? |
EC Number | Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|---|
3.4.22.26 | 37 | - |
assay at | Homo sapiens |
3.4.22.26 | 37 | - |
assay at | Rattus norvegicus |